TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VYKOURA

LEUCOVORIN CALCIUM
Oncology Approved 2026-02-03
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-02-03
Routes
INTRAMUSCULAR, INTRAVENOUS
Dosage Forms
SOLUTION

Companies

Active Ingredient: LEUCOVORIN CALCIUM

VYKOURA Approval History

Loading approval history...

What VYKOURA Treats

5 indications

VYKOURA is approved for 5 conditions since its original approval in 2026. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Methotrexate Toxicity
  • Folic Acid Antagonist Toxicity
  • Dihydrofolate Reductase Inhibitor Toxicity
  • Megaloblastic Anemia
  • Metastatic Colorectal Cancer
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VYKOURA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

VYKOURA is indicated for: 1.1 Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients. 1.2 Reducing the toxicity of: Methotrexate in adult and pediatric patients with impaired methotrexate elimination or Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients. 1.3 Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible. 1.4 Treatment of patients with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.